Search

Your search keyword '"Chen, Ling-Xiao"' showing total 151 results
Start Over Author "Chen, Ling-Xiao"
151 results on '"Chen, Ling-Xiao"'

5. Applications of magnetic solid‐phase extraction in the sample preparation of natural product analysis (2020–2023).

Author

Chen, Ling‐Xiao and Yang, Feng‐Qing

Subjects
*SOLID phase extraction, *NATURAL products, *MAGNETICS, *COMPLEX matrices, *MATRIX multiplications, *ORGANIC solvents
Abstract

Sample preparation, including extraction, separation, and purification, is a vital process for natural product analysis. As an attractive sample pretreatment method, magnetic solid‐phase extraction (MSPE) has gained plenty of attention, mainly due to its simpler operation, less consumption of organic solvents, and shorter processing time than traditional SPE. This updated review is devoted to summarizing the applications of MSPE based on different magnetic nanomaterials in the analysis of various natural products in complex matrixes, such as biological samples, plants, and Chinese herbal preparations in the past four years (2020–2023). The preparation and fabrication of different materials are briefly introduced. Furthermore, the extraction mechanism and interaction forces between adsorbent and analytes are elaborated, and the advantages and disadvantages of different adsorbents coupled with various analytical methods for MSPE of different natural products are summarized. Moreover, the future trends and opportunities for MSPE in the natural product analysis are discussed. It is expected that this work can provide updated information for future research on the applications of MSPE in such fields. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Additional file 1 of Comparison of volatile compounds in different parts of fresh Amomum villosum Lour. from different geographical areas using cryogenic grinding combined HS–SPME–GC–MS

Author

Chen, Ling-Xiao, Lai, Yun-Feng, Zhang, Wei-Xiong, Cai, Jing, Hu, Hao, Wang, Ying, Zhao, Jing, and Li, Shao-Ping

Abstract

Additional file 1: Fig.S1. The chromatogram of A. villosum samples. I, fruit (S1-S18); II, root (S19-S36); III, leaf (S37-S54); IV, stem (S55-S72). Table S1. The main volatile compounds in 72 A. villosum samples.

Published
2020
Full Text
View/download PDF

29. Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation

Author

Kan, Shun-Li, Ning, Guang-Zhi, Chen, Ling-Xiao, Zhou, Yong, Sun, Jing-Cheng, and Feng, Shi-Qing

Subjects
Postoperative Complications, Bone Density Conservation Agents, Diphosphonates, Bone Density, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Humans, Bone Diseases, Kidney Transplantation, Systematic Review and Meta-Analysis, Research Article, Randomized Controlled Trials as Topic
Abstract

Supplemental Digital Content is available in the text, In patients with low bone mineral density (BMD) after kidney transplantation, the role of bisphosphonates remains unclear. We performed a systematic review and meta-analysis to investigate the efficacy and safety of bisphosphonates. We retrieved trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception through May 2015. Only randomized controlled trials that compared bisphosphonate-treated and control groups of patients with low bone mineral density after kidney transplantation were included. The primary outcomes were the percent change in BMD, the absolute change in BMD, and the BMD at the end of study at the lumbar spine. The results were expressed as the mean difference (MD) or relative risk (RR) with the 95% confidence interval (CI). We used a random-effects model to pool the outcomes. We included 17 randomized controlled trials with 1067 patients. Only 1 included trial was found to be at low risk of bias. The rest of the included studies were found to have high to uncertain risk of bias. Compared with the control group, those who received bisphosphonates had a significant increase in percent change in BMD (mean difference [MD] = 5.51, 95% confidence interval [CI] 3.22–7.79, P

Published
2016

35. The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease

Author

Chen, Yu Jie, Chen, Ling Xiao, Han, Mei Xiang, Zhang, Tian Song, Zhou, Zhi Rui, and Zhong, Dian Sheng

Subjects
Lung Neoplasms, Prognosis, Disease-Free Survival, Survival Rate, Treatment Outcome, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Disease Progression, Humans, Lung Diseases, Interstitial, Systematic Review and Meta-Analysis, Research Article
Abstract

Supplemental Digital Content is available in the text, Chemotherapy plays a critical and venturous role against the co-morbidity of nonsmall cell lung cancer and interstitial lung disease (NSCLC–ILD). We performed a Bayesian meta-analysis and systematic review to evaluate the safety and efficacy of the chemotherapy in NSCLC–ILD patients. EMBASE, PubMed, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov (up to January 2015). We included all study designs except case reports, all studies with NSCLC–ILD patients and all the possible chemotherapy regimens. Quality was assessed by a components approach. We derived summary estimates using Bayesian method through WinBUGS (version 1.4.3, MRC Biostatistics Unit, Cambridge, UK). Seven studies involving 251 patients with NSCLC–ILD were included in the meta-analysis. The treatment response (complete remission, 0; [partial remission, 39.1%; 95% credible interval [CrI], 32.6–45.7]; [stable disease, 36%; 95% CrI, 29.6–42.2]; [PD, 15.4%; 95% CrI, 11.3–19.8]; [nonevaluable, 6.4%; 95% CrI, 2.7–10.1]; [overall response rate, 41.3%; 95% CrI, 35.3–47.4]; [disease control rate, 77.7%; 95% CrI, 72.2–82.7]) were comparable to that of patients with NSCLC alone; the survival outcomes (median overall survival, median progression-free survival, and 1-year survival rate) were slightly worse, especially the lower 1-year survival rate. Platinum-based doublets as first-line chemotherapy may be related to higher incidence of acute exacerbation-ILD in first line chemotherapy (AE, 8.47%; 95% CrI, 5.04–12.6). The data selection bias and small patient number make the meta-analysis of treatment response and conclusions generated from these data inaccurate. The present meta-analysis suggests that chemotherapy might be an effective therapy for patients with NSCLC–ILD, but it might be associated with higher incidence of acute exacerbation.

Published
2015

36. Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty

Author

Kan, Shun-Li, Yang, Bo, Ning, Guang-Zhi, Chen, Ling-Xiao, Li, Yu-Lin, Gao, Shi-Jie, Chen, Xing-Yu, Sun, Jing-Cheng, and Feng, Shi-Qing

Subjects
musculoskeletal diseases, Models, Statistical, Postoperative Complications, Treatment Outcome, Arthroplasty, Replacement, Hip, Ossification, Heterotopic, Anti-Inflammatory Agents, Non-Steroidal, Humans, Bayes Theorem, digestive system diseases, Article, Systematic Review and Meta-Analysis
Abstract

Heterotopic ossification (HO) is a frequent complication after total hip arthroplasty (THA). Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used as routine prophylaxis for HO after THA. However, the efficacy of NSAIDs on HO, particularly selective NSAIDs versus nonselective NSAIDs, is uncertain. We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov to identify randomized controlled trials with respect to HO after THA. Two reviewers extracted the data and estimated the risk of bias. For the ordered data, we followed the Bayesian framework to calculate the odds ratio (OR) with a 95% credible interval (CrI). For the dichotomous data, the OR and 95% confidence interval (CI) were calculated using Stata version 12.0. The subgroup analyses and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach were used. A total of 1856 articles were identified, and 21 studies (5995 patients) were included. In the NSAIDs versus placebo analysis, NSAIDs could decrease the incidence of HO, according to the Brooker scale (OR = 2.786, 95% CrI 1.879–3.993) and Delee scale (OR = 9.987, 95% CrI 5.592–16.17). In the selective NSAIDs versus nonselective NSAIDs analysis, there was no significant difference (OR = 0.7989, 95% CrI 0.5506–1.125) in the prevention of HO. NSAIDs could increase discontinuation caused by gastrointestinal side effects (DGSE) (OR = 1.28, 95% CI 1.00–1.63, P = 0.046) more than a placebo. Selective NSAIDs could decrease DGSE (OR = 0.48, 95% CI 0.24–0.97, P = 0.042) compared with the nonselective NSAIDs. There was no significant difference with respect to discontinuation caused by nongastrointestinal side effects (DNGSE) in NSAIDs versus a placebo (OR = 1.16, 95% CI 0.88–1.53, P = 0.297) and in selective NSAIDs versus nonselective NSAIDs (OR = 0.83, 95% CI 0.50–1.37, P = 0.462). NSAIDs might reduce the incidence of HO and increase DGSE in the short-term.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results